['chronic kidney disease', 'hyperphosphatemia', 'iron deficiency anemia', 'renal insufficiency']
['ferric citrate']

        Inclusion Criteria:

          1. Age >18 years at screening visit

          2. Serum phosphate > or equal to 3.0 mg/dL obtained at screening

          3. CKD with eGFR < or equal to 20 mL/min obtained at screening*

          4. Hemoglobin (Hgb) >8.0 g/dL obtained at screening

          5. TSAT <55% obtained at screening

          6. Females of child bearing potential with negative serum pregnancy test obtained at
             screening

          7. Willing and able to give written informed consent

          8. Anticipated to have > or equal to 8 weeks prior to need for initiating RRT in the
             opinion of the investigator

        Exclusion Criteria:

          1. Liver enzymes (ALT/AST) >X3 times upper limit of normal at screening

          2. Use of IV iron, blood transfusions or ESA agents within 2 weeks prior to the screening
             visit and prior to the Day 1 visit.

          3. Evidence of acute kidney injury (i.e., no CKD) or planned need for RRT within 12 weeks
             of screening

          4. Scheduled kidney transplant within 24 weeks of screening

          5. Contra-indication to ferric citrate: iron overload syndrome, allergic reaction or
             known intolerance to ferric citrate

          6. Clinically significant medical condition felt to interfere with tolerance of oral
             medication

          7. Life expectancy < 6 months or confirmed conviction that subject does NOT want to
             initiate RRT despite a decline in kidney function

          8. Active drug or alcohol dependence or abuse (excluding tobacco use or marijuana use)
             within the 12 months prior to screening (in the opinion of the PI)

          9. Psychiatric disorder that interferes with the subject's ability to comply with the
             study protocol in the opinion of the PI

         10. Any other medical condition that, in the opinion of the PI, renders the subject unable
             to or unlikely to complete the trial or that would interfere with optimal
             participation in the trial or produce significant risk to the subject

         11. Inability to cooperate with study personnel or study procedures

         12. Females who are pregnant or breastfeeding

         13. Receiving or has received any investigational drug with in the past 30 days prior to
             the Day 1 visit
      